RE:RE:$2.67 is Fair Value
Josh Blair, Vice-Chair and Director ... Blair was seen as a possible successor to the CEO at Telus. He remains Chair Emeritus at Telus Health, where he has had a leading role for the past decade. He has digital health industry smarts, contacts and knowledge. So, Blair is not some dummy director who is going to lend his name to any public company for a few dollars in return. He doesn't need the money. At this stage reputation is more valuable. Someone in his position can pick and choose which companies to join. Blair's participation in CRBK alone is not reason enough to invest; but it sure is worth considering that Blair has skin the game.